Physician profile
Mandy L Maneval
NPI 1407064207
$2,067.06
in general payments reported to CMS, 2019-2025
21 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $87.53 · 2021: $256 · 2022: $233 · 2023: $388 · 2024: $263 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $418.84 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $399.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $274.15 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $140.16 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $135.03 | 2019-2025 | |
| Dexcom, INC. | $121.54 | 2023-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $95.62 | 2019-2022 | |
| Lilly USA, LLC | $62.08 | 2019-2023 | Jardiance, Emgality |
| Abbott Laboratories | $61.57 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.72 | 2019-2022 | |
| Amgen INC. | $48.61 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.24 | 2022-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $45.17 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $32.19 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.76 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.97 | 2019-2020 | |
| Allergan, INC. | $20.41 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.15 | 2023 | |
| Sanofi-Aventis U.S. LLC | $12.27 | 2020 | |
| Daiichi Sankyo INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Maneval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.